Información del artículo
Resumen
El aumento de la esperanza de vida ha llevado a un incremento en la incidencia de enfermedades crónicas como la demencia. Tratar los factores de riesgo de la demencia, como la depresión, podría reducir su incidencia. Sin embargo, el tratamiento con antidepresivos no ha sido eficaz en el manejo de este síntoma, lo que aumenta el riesgo de demencia en el futuro. Es fundamental investigar las causas y el tratamiento de la depresión, y el uso de modelos animales es importante en este sentido. Este estudio busca analizar la relación entre la depresión y el riesgo de desarrollar demencia, así como los modelos preclínicos más relevantes para estudiar la depresión en roedores.
Palabras clave:
Demencia
Depresión
Disfunción cognitiva
Factor de riesgo
Modelos animales
Modelos preclínicos
Abstract
The increase in life expectancy has led to a rise in the incidence of chronic diseases, such as dementia. Treating the risk factors of dementia, such as depression, could help reduce its occurrence. However, antidepressant treatment has not proven effective in managing this symptom, thereby increasing the risk of dementia in the future. It is essential to investigate the causes and treatment of depression, and in this regard, the use of animal models is of great significance. This study aims to analyze the evidence supporting the relationship between depression and the risk of developing dementia, while also providing an update on the most relevant preclinical models for studying depression in rodents.
Keywords:
Dementia
Depression
Cognitive dysfunction
Risk factor
Animal models
Preclinical models
Artículo
Opciones para acceder a los textos completos de la publicación Psiquiatría Biológica
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
G. Collaborators, E. Nichols, F. Abd-Allah, A. Abdoli, A.E. Abosetugn, W.A. Abrha, et al., Global mortality from dementia: application of a new method and results from the Global Burden of Disease Study 2019, 7 (1), 2021, e12200.
[2]
A.H. Balka, P.O. Sandman, B. Winblad.
Dementia–Etiology and epidemiology. A systematic review. The Swedish Council on Technology Assessment in Health Care, (2008), pp. 514
[3]
WHO.
Dementia.
[4]
J.M. Long, D.M. Holtzman.
Alzheimer disease: an update on pathobiology and treatment strategies.
Cell., 179 (2019), pp. 312-339
[5]
S. Norton, F. Matthews, D. Barnes, K. Yaffe, C. Brayne.
Potential for primary prevention of Alzheimer’s disease: an analysis population-based data.
Lancet Neurol, 13 (2014), pp. 788-794
[6]
O. Almeida, G. Hankey, B. Yeap, J. Golledge, L. Flicker.
Depression as a modifiable factor to decrease the risk of dementia.
Transl Psychiatry, 7 (2017), pp. 1-6
[7]
G. Livingston, J. Huntley, A. Sommerlad, D. Ames, C. Ballard, S. Banerjee, et al.
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.
, 396 (2020), pp. 413-446
[8]
F.S. Dafsari, F.J.T.P. Jessen.
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease.
, 10 (2020), pp. 160
[9]
S.M. Gold, O. Köhler-Forsberg, R. Moss-Morris, A. Mehnert, J.J. Miranda, M. Bullinger, et al.
Comorbid depression in medical diseases.
, 6 (2020), pp. 69
[10]
A. Jamieson, A.M. Goodwill, M. Termine, S. Campbell, C. Szoeke.
Depression related cerebral pathology and its relationship with cognitive functioning: a systematic review.
J Affect Disord, 250 (2019), pp. 410-418
[11]
World-Health Organization.
Depressive Disorder (Depression).
[12]
J.A. Hamer, D. Testani, R.B. Mansur, Y. Lee, M. Subramaniapillai, McIntyre RS.
Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression.
, 315 (2019), pp. 1-8
[13]
F. Darcet, A.M. Gardier, R. Gaillard, D.J. David, J.-P. Guilloux.
Cognitive dysfunction in major depressive disorder. A translational review in animal models of the disease.
Pharmaceuticals., 9 (2016), pp. 9
[14]
K. Palmer, L. Fratiglioni, B. Winblad.
What is mild cognitive impairment? variations in definitions and evolution of nondemented persons with cognitive impairment.
, 107 (2003), pp. 14-20
[15]
S.L. Naismith, I.B. Hickie, K. Turner, C.L. Little, V. Winter, P.B. Ward, et al.
Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors.
, 25 (2003), pp. 866-877
[16]
J.D. Bastida, N.P. Pomés, S.J. Font, A.F. Eickhoff.
La depresión: un predictor de demencia.
Rev Esp Geriatr Gerontol, 51 (2015), pp. 112-118
[17]
M.A. Butters, J.T. Becker, R.D. Nebes, M.D. Zmuda, B.H. Mulsant, B.G. Pollock.
Changes in cognitive functioning following treatment of late-life depression.
Am J Psychiatry, 157 (2000), pp. 1949-1954
[18]
A.L. Byers, K. Yaffe.
Depression and risk of developing dementia.
Nat Rev Neurol, 7 (2011), pp. 323-331
[19]
F. Caraci, A. Copani, F. Nicoletti, F. Drago.
Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets.
Eur J Pharmacol, 626 (2010), pp. 64-71
[20]
G.S. Alexopoulos.
Mechanisms and treatment of late-life depression.
Transl Psychiatry, 9 (2019), pp. 188
[21]
M.A. Butters, J.B. Young, O. Lopez.
Pathways linking late-life depression to persistent cognitive impairment and dementia.
Dialogues Clin Neurosci, 10 (2008), pp. 345-357
[22]
N. Pomara, D. Bruno, C.R. Plaska, J. Ramos-Cejudo, R.S. Osorio, A. Pillai, et al.
Plasma amyloid-β dynamics in late-life major depression: a longitudinal study.
Transl Psychiatry, 12 (2022), pp. 301
[23]
M. Maes, R. Yirmyia, J. Noraberg, S. Brene, J. Hibbeln, G. Perini, et al.
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.
Metab Brain Dis, 24 (2009), pp. 27-53
[24]
R.B. Maccioni, L.E. Rojo, J.A. Fernández, R.O. Kuljis.
The role of neuroimmunomodulation in Alzheimer’s disease.
Ann N Y Acad Sci, 1153 (2009), pp. 240-246
[25.]
F. Fumagalli.
Neurotrophic factors in neurodegenerative disorders: potential for therapy.
CNS Drugs, 22 (2008), pp. 1005-1019
[26]
S. Anttila, K. Huuhka, M. Huuhka, R. Rontu, M. Hurme, E. Leinonen, et al.
Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression.
J Neural Transm, 114 (2007), pp. 1065-1068
[27]
B. Borroni, S. Archetti, C. Costanzi, M. Grassi, M. Ferrari, A. Radeghieri, et al.
Role of BDNF Val66Met functional polymorphism in Alzheimer’s diseaserelated depression.
Neurobiol Aging, 30 (2009), pp. 1406-1412
[28]
J.W. Murrough, B. Iacoviello, A. Neumeister, D.S. Charney, D.V. Iosifescu.
Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies.
Neurobiol Learn Mem, 96 (2011), pp. 553-563
[29]
E.A. Crocco, K. Castro, A.A. Loewenstein.
How late-life depression afects cognition: neural mechanisms.
Curr Psychiatry Rep, 12 (2010), pp. 34-38
[30]
R.S. McIntyre, S. Lophaven, C.K. Olsen.
A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive dysfunction in depressed adults.
Int J Neuropsychopharmacol, 17 (2014), pp. 1557-1567
[31]
M. Talarowska, M. Zajączkowska, P. Gałecki.
Cognitive functions in first-episode depression and recurrent depressive disorder.
Psychiatr Danub, 27 (2015), pp. 38-43
[32]
G. Sanacora, M.A. Smith, S. Pathak, H.L. Su, P.H. Boeijinga, D.J. McCarthy, et al.
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Mol Psychiatry, 19 (2014), pp. 978-985
[33]
G.I. Papakostas.
Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.
J Clin Psychiatry, 75 (2013), pp. 8-14
[34]
B. Solé, E. Jimenez, A. Martinez-Aran, E. Vieta.
Cognition as atarget in major depression: new developments.
Eur Neuropsychopharmacol, 25 (2015), pp. 231-247
[35]
C.M. Olbert, G.J. Gala, L.A. Tupler.
Quantifying heterogeneity attributable to polythetic diagnostic criteria: theoretical framework and empirical application.
J Abnorm Psychol, 123 (2014), pp. 452-462
[36]
B. Planchez, A. Surget, C. Belzung.
Animal models of major depression: drawbacks and challenges.
J Neural Transm, 126 (2019), pp. 1383-1408
[37]
C.H. Duman.
Models of depression.
Vitam Horm, 82 (2010), pp. 1-21
[38]
S.L. Andersen.
Exposure to early adversity: points of crossspecies translation that can lead to improved understanding of depression.
Dev Psychopathol, 27 (2015), pp. 477-491
[39]
S.G. Tractenberg, M.L. Levandowski, L.A. de Azeredo.
An overview of maternal separation efects on behavioural outcomes in mice: evidence from a four-stage methodological systematic review.
Neurosci Biobehav Rev, 68 (2016), pp. 489-503
[40]
C. Becker, B. Zeau, C. Riva.
Repeated social defeat induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin.
Mol Psychiatry, 13 (2008), pp. 1079-1092
[41]
M. Nollet, A.M.L. Guisquet, C. Belzung.
Models of depression: unpredictable chronic mild stress in mice.
Curr Protoc Pharmacol, 5 (2013), pp. 65
[42]
X. Zhao, F. Cao, Q. Liu, X. Li, G. Xu, G. Liu, et al.
Behavioral, inflammatory and neurochemical disturbances in LPS and UCMS-induced mouse models of depression.
Behav Brain Res, 364 (2019), pp. 494-502
[43]
J.L. Price, W.C. Drevets.
Neural circuits underlying the pathophysiology of mood disorders.
Trends Cogn Sci, 16 (2012), pp. 61-71
